×
Amgen Cash on Hand 2010-2024 | AMGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amgen cash on hand for the quarter ending September 30, 2024 was
$9.011B
, a
74.06% decline
year-over-year.
Amgen cash on hand for 2023 was
$10.944B
, a
17.61% increase
from 2022.
Amgen cash on hand for 2022 was
$9.305B
, a
15.78% increase
from 2021.
Amgen cash on hand for 2021 was
$8.037B
, a
24.51% decline
from 2020.
View More
Amgen Cash on Hand 2010-2024 | AMGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amgen cash on hand for 2023 was
$10.944B
, a
17.61% increase
from 2022.
Amgen cash on hand for 2022 was
$9.305B
, a
15.78% increase
from 2021.
Amgen cash on hand for 2021 was
$8.037B
, a
24.51% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Bristol Myers Squibb (BMY)
$119.4B
Vertex Pharmaceuticals (VRTX)
$116.1B
Gilead Sciences (GILD)
$112.4B
CSL (CSLLY)
$87.2B
Regeneron Pharmaceuticals (REGN)
$81.1B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$31.6B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$23B
Illumina (ILMN)
$22.2B
BeiGene (BGNE)
$18.6B
Moderna (MRNA)
$15.8B
Incyte (INCY)
$13.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.2B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.9B
Legend Biotech (LEGN)
$7.5B